"There's a huge amount of suffering that is generated not by the actual challenges in life but by the fictitious problems that the mind generates." - Eckhart Tolle
Following the EUA of our #antibody cocktail for #COVID19, our Founder & CEO Len Schleifer reflects on how we got here and what’s still ahead for our team in a #RegeneronPerspectives blog.
Announcing positive data from 524 additional non-hospitalized #COVID19 patients in ongoing P2/3 study of Regeneron’s investigational antibody cocktail: https://t.co/FOVKNlZRn0
We are collaborating with @Roche to significantly increase global supply of Regeneron’s investigational antibody cocktail for #COVID19: https://t.co/A4i6ZZh482
For the second consecutive year, we have been named as one of @FastCompany's 2020 Best Workplaces for Innovators. Learn how we foster a collaborative culture driven by #science: https://t.co/UMGQRAs2TM #FCBestWorkplaces
With @Sanofi, we're announcing clinically meaningful results from a pivotal Phase 2 clinical trial for our #immunotherapy in advanced #basalcell#carcinoma (BCC). Learn more: https://t.co/dFCrEbLuai
This is bad. We're doing it wrong.
"We've been at persistent ~30k new cases, 2k daily deaths daily for more than a month."
Hardest hit states are cutting new cases & daily deaths.
*Rest of the country* is now the fuel for our daily case & death numbers, which are not dropping.
Regeneron and @Sanofi provide update on U.S. Phase 2/3 trial of repurposed IL-6 inhibitor medicine (currently approved for rheumatoid arthritis) in hospitalized COVID-19 patients https://t.co/8KAZob0Nfd
As we discover and develop important new medicines, we strive to integrate a sustainable approach into all aspects of our business. Look out for our 2019 Responsibility Report this Friday for more insight into our sustainability efforts. #EarthDay#ResponsibleRegeneron
#COVID19 program update: We have moved our top SARS-CoV-2-neutralizing antibodies into preclinical- and clinical-scale cell production lines & remain on track to have supply available for clinical studies in June. Read on: https://t.co/w3wjPjXlmB
Our CSO George Yancopoulos discussed on @CNNi how we’re applying lessons from our #Ebola research to finding a potential medicine for #COVID19. Watch via w/ @jchatterleyCNN
A #PassiveVaccine for #COVID19? What about a drug that might mean less ventilator use? Biotech giant @Regeneron is working on both. A fascinating convo with Dr. George Yancopolous CSO, on the science race to save lives.
#CoronavirusOutbreak